Litcius/Paper detail

Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

Benjamin Ungar, Ana B. Pavel, Randall Li, Grace W. Kimmel, John K Nia, Peter W. Hashim, Hee Jin Kim, Margot Chima, Anjali S. Vekaria, Yeriel Estrada, Hui Xu, Xiangyu Peng, Giselle Singer, Danielle Baum, Yasaman Mansouri, Mark Taliercio, Emma Guttman‐Yassky

2020Journal of Allergy and Clinical Immunology123 citationsDOI

Topics & Concepts

Atopic dermatitisDupilumabMedicineSecukinumabEczema Area and Severity IndexAllergyDermatologyImmunologyPsoriasisPsoriatic arthritisDermatology and Skin DiseasesAllergic Rhinitis and SensitizationAsthma and respiratory diseases
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis | Litcius